Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab).